drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous gene-modified T-cell therapy engineered to express a chimeric antigen receptor targeting mesothelin (MSLN) on ovarian cancer cells. CAR engagement activates CD3ζ/costimulatory signaling, inducing cytokine release and perforin/granzyme-mediated cytotoxicity. Administered as a single IV infusion in dose-escalation cohorts (1×10^6, 3×10^6, 1×10^7, 2×10^7 cells/kg) for advanced, platinum-resistant, MSLN-positive ovarian cancer.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that recognizes mesothelin on tumor cells. CAR engagement activates CD3ζ and costimulatory signaling, inducing T‑cell activation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of mesothelin‑positive ovarian cancer cells.
drug_name
TCR-like CAR-T
nct_id_drug_ref
NCT05963100